Tetraneuron

Tetraneuron is a drug discovery company, focused on the development of a disruptive Gene Therapy for Alzheimer’s disease (AD) and an Early Biomarker for this neurodegenerative condition.

Locations
Año Fundación
2012
Funding Stage
Series A (from 1 to less than 5 M EUR)
Número Empleados
2-10
Targets
Categorías